Four gene biomarkers, SOCS3, MYC, TGIF1, and LETM2, have been identified to accurately diagnose post-transplant acute kidney injury (AKI). This new study leveraged integrated transcriptomic, single-cell, animal, and human clinical data, validating the gene signature through extensive cohort analyses.
AKI occurs frequently post-renal transplant, mainly due to ischaemia reperfusion injury (IRI). Despite its significance, dependable biomarkers for early detection have been lacking.
Through weighted gene co-expression network and differential expression analysis, researchers identified 222 candidate genes related to early allograft IRI, refining these to a four-gene model with an impressive training cohort AUC of 0.969.
Validation in independent cohorts revealed consistent high accuracy, evidenced by an AUC of 0.942 in a large external dataset. This gene panel showed superior performance against existing biomarkers, enhancing early detection capabilities in transplant medicine.
Further biological evidence demonstrated increased expression of the four genes in renal AKI samples, reinforcing their diagnostic potential as early biomarkers. Researchers advocate for larger clinical trials to confirm effectiveness and integration into practice.